Sammenlignet med placebo nedsatte Fablyn- behandling risikoen for invasiv mammacancer med 85% (placebo:
Over the 5 years of the PEARL study (involving 8,556 patients), FABLYN treatment compared to placebo reduced the risk of invasive breast cancer by 85% (placebo: